image
Healthcare - Biotechnology - NASDAQ - US
$ 1.69
12.1 %
$ 222 M
Market Cap
-0.84
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PRME stock under the worst case scenario is HIDDEN Compared to the current market price of 1.69 USD, Prime Medicine, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PRME stock under the base case scenario is HIDDEN Compared to the current market price of 1.69 USD, Prime Medicine, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PRME stock under the best case scenario is HIDDEN Compared to the current market price of 1.69 USD, Prime Medicine, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PRME

image
$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
2.98 M REVENUE
0.00%
-202 M OPERATING INCOME
-5.84%
-196 M NET INCOME
1.14%
-123 M OPERATING CASH FLOW
25.72%
68.5 M INVESTING CASH FLOW
265.86%
196 M FINANCING CASH FLOW
29804.73%
2.18 M REVENUE
944.50%
-44.2 M OPERATING INCOME
18.46%
-42.3 M NET INCOME
19.50%
16.2 M OPERATING CASH FLOW
162.69%
48.3 M INVESTING CASH FLOW
-4.15%
1 K FINANCING CASH FLOW
-100.00%
Balance Sheet Prime Medicine, Inc.
image
Current Assets 212 M
Cash & Short-Term Investments 185 M
Receivables 0
Other Current Assets 26.4 M
Non-Current Assets 85.6 M
Long-Term Investments 0
PP&E 71.6 M
Other Non-Current Assets 14.1 M
62.34 %8.88 %24.05 %4.73 %Total Assets$297.5m
Current Liabilities 38 M
Accounts Payable 11.4 M
Short-Term Debt 3.61 M
Other Current Liabilities 23 M
Non-Current Liabilities 106 M
Long-Term Debt 37.2 M
Other Non-Current Liabilities 69.2 M
7.86 %15.93 %25.76 %47.95 %Total Liabilities$144.4m
EFFICIENCY
Earnings Waterfall Prime Medicine, Inc.
image
Revenue 2.98 M
Cost Of Revenue 0
Gross Profit 2.98 M
Operating Expenses 205 M
Operating Income -202 M
Other Expenses -6.58 M
Net Income -196 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)3m03m(205m)(202m)7m(196m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-6787.36% OPERATING MARGIN
-6787.36%
-6566.61% NET MARGIN
-6566.61%
-127.90% ROE
-127.90%
-65.84% ROA
-65.84%
-76.94% ROIC
-76.94%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Prime Medicine, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)202020202021202120222022202320232024202420252025
Net Income -196 M
Depreciation & Amortization 6.13 M
Capital Expenditures -7.29 M
Stock-Based Compensation 26.1 M
Change in Working Capital 31.1 M
Others 46.1 M
Free Cash Flow -130 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Prime Medicine, Inc.
image
Wall Street analysts predict an average 1-year price target for PRME of $16.8 , with forecasts ranging from a low of $12 to a high of $23 .
PRME Lowest Price Target Wall Street Target
12 USD 610.06%
PRME Average Price Target Wall Street Target
16.8 USD 894.08%
PRME Highest Price Target Wall Street Target
23 USD 1260.95%
Price
Max Price Target
Min Price Target
Average Price Target
25252020151510105500Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.8 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.4001.4001.2001.2001.0001.0000.8000.8000.6000.6000.4000.4000.2000.2000.0000.0000.1660.1120.1460.20.160.0660.2330.80.090.440.7270.940.8611.250.2131.210.002015201520162016201720172018201820192019
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Prime Medicine, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Prime Drink Group Provides an Update to Its Subsidiary Restructuring MONTREAL, April 07, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to the termination of the forbearance agreements Roynat Inc. (“Roynat”), Financement Agricole Canada (“FAC”) and Banque Canadienne Impériale de Commerce (“CIBC” and together with Roynat and FAC, the “Creditors”) “principal creditors” have filed an application pursuant to Section 243 of the Bankruptcy and Insolvency Act (Canada) with the Superior Court, District of Montréal (the “Application”), to have a receiver appointed with respect to the assets of Prime's wholly-owned subsidiary, Triani Canada Inc (“Triani”). globenewswire.com - 3 weeks ago
Why Prime Medicine Stock Was Climbing Higher This Week News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock over 12% higher week to date as of early Thursday evening. fool.com - 1 month ago
Why Prime Medicine Stock Is Soaring Today Shares of Prime Medicine (PRME 12.50%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m. fool.com - 1 month ago
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) -- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- globenewswire.com - 1 month ago
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates -- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in 1H 2026 -- -- Additional high-value programs advancing through preclinical development -- CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2024 and provided a business update. globenewswire.com - 2 months ago
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D. globenewswire.com - 2 months ago
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm NEW YORK , Jan. 30, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prime Medicine, Inc. (NASDAQ: PRME) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. prnewswire.com - 3 months ago
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies Prime Medicine's proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME's pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson's Disease, with clinical data expected in 2025. PRME's strategic collaboration with Bristol Myers provided $55 million in cash upfront, a $55 million equity stake, $3.5B in potential milestone payments, and diversification into ex vivo T-cell therapies. seekingalpha.com - 5 months ago
Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Wilson Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Wilson Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. "Wilson Disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wilson Disease pipeline landscape is provided which includes the disease overview and Wilson Disease treatment guidelines. The assessment part of the report embraces, in depth Wilson Disease commercial assessment and clinical assessment of the pipeline products under development. globenewswire.com - 5 months ago
Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: globenewswire.com - 5 months ago
12 High-Growth Stocks That Could Deliver Parabolic Returns These 12 innovative companies could deliver exponential returns over the next quarter century. fool.com - 6 months ago
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies globenewswire.com - 6 months ago
8. Profile Summary

Prime Medicine, Inc. PRME

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 222 M
Dividend Yield 0.00%
Description Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Contact 21 Erie Street, Cambridge, MA, 02139 https://www.primemedicine.com
IPO Date Oct. 20, 2022
Employees 214
Officers Dr. Meredith Goldwasser Senior Vice President and Head of Strategy & Corporate Operations Dr. Jeremy S. Duffield M.D., Ph.D. Chief Scientific Officer Dr. Karen Brown J.D., Ph.D. Senior Vice President of Intellectual Property & Legal Affairs Ms. Carman Alenson CPA, M.B.A. Senior Vice President of Finance & Chief Accounting Officer Dr. Keith Michael Gottesdiener M.D., Ph.D. President, Chief Executive Officer, Secretary & Director Ms. Niamh Alix Chief Human Resources Officer Dr. Allan Reine M.D. Chief Financial Officer Dr. Andrew Anzalone M.D., Ph.D. Co-Founder & Head of Prime Editing Platform Dr. Ann L. Lee Ph.D. Chief Technical Officer Dr. David R. Liu Ph.D. Co-Founder & Member of Scientific Advisory Board